IBI Ag was founded and incubated by Trendlines, and its proprietary platform adapts single-domain antibody technology from human therapeutics to agriculture, enabling the development of precise, environmentally responsible bioinsecticides.
This approach has the potential to transform pest management by protecting high value crops while preserving beneficial insect species.
The $10 million financing round is led by Corteva, through its Corteva Catalyst platform. The round included participation from The Trendlines Group, Iron Nation, Consensus Business Group, Bandera Capital, First Imagine Ventures, and a grant from the Israel Innovation Authority.
The investment will allow IBI Ag to accelerate product development and regulatory progress, advancing its next-generation biological pest control solutions toward global markets.
“IBI Ag’s achievement is a strong validation of the quality and commercial potential within the Trendlines portfolio,” added Haim Brosh, CEO of Trendlines. “We are proud to support companies that not only deliver innovation but also create meaningful impact in sustainability and food security.”
Shares in Trendline Group closed flat at 6.2 cents on Nov 12.
